P/E Ratio

Genmab's $8 billion acquisition of Merus isn't just a deal; it's a bold strategy to own its destiny and dominate the future of oncology therapeutics.

A $2.4B deal for Alphawave IP and a revealing investor filing pull back the curtain on the high-stakes race to build the infrastructure for an AI world.

A prestigious Yale recognition for board member Dr. Curtis Patton bolsters Tevogen's credibility as it advances its AI and T-cell platforms.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.